Global HIV Antivirals Market Growth 2024-2030

Global HIV Antivirals Market Growth 2024-2030

Product Code:1224077

Published Date: Sep 06,2024

Pages: 94

Region: Global

Category: Pharma & Healthcare

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

HIV antivirals are medications used to manage HIV infection by inhibiting the virus's ability to replicate and spread. They work by targeting different stages of the HIV life cycle. These drugs are often used in combination to effectively control the virus and improve the quality of life for people living with HIV.

The global HIV Antivirals market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “HIV Antivirals Industry Forecast” looks at past sales and reviews total world HIV Antivirals sales in 2023, providing a comprehensive analysis by region and market sector of projected HIV Antivirals sales for 2024 through 2030. With HIV Antivirals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Antivirals industry.

This Insight Report provides a comprehensive analysis of the global HIV Antivirals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Antivirals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Antivirals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Antivirals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Antivirals.

United States market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key HIV Antivirals players cover Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly 
 % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of HIV Antivirals market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Fixed Dose Combinations (FDCs)
    Integrase Strand Transfer Inhibitors (lNSTls)
    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
    Entry Inhibitors -CCR5 co-receptor antagonist
    Protease Inhibitors (Pls)
    Nucleoside Reverse Transcriptase lnhibitors (NRTls)
    Others

Segmentation by Application:
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Gilead Sciences
    ViiV Healthcare
    Johnson & Johnson (Janssen Pharmaceuticals)
    Merck & Co.
    AbbVie
    Bristol-Myers Squibb
    Roche
    Teva Pharmaceuticals

Key Questions Addressed in this Report
What is the 10-year outlook for the global HIV Antivirals market?
What factors are driving HIV Antivirals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HIV Antivirals market opportunities vary by end market size?
How does HIV Antivirals break out by Type, by Application?